CClinicalTrials.gg
CompletedNCT01111357HLAPRPAUpdated Dec 21, 2010

Study of Human Leukocyte Antigen (HLA) Polymorphisms in Patients With Rheumatoid Arthritis

An observational study in Rheumatoid Arthritis, sponsored by University Hospital Center of Martinique. Completed at 1 site in Martinique. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-12-21.

Sponsored by University Hospital Center of Martinique · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

Rheumatoid arthritis (RA), affects between 0.3% and 1.0% of the population, it can lead to progressive joint destruction and severe disability. To date, two RA genetic susceptibility factors have been identified: HLA-DRB1-SE (Shared epitope) and PTPN22 620W alleles. The predictive value of the alleles for diagnosis of RA was previously investigated in cohorts of caucasians patients with early unclassified arthritis that showed restrained association between RA and HLA-SE. Despite the contribution of HLA to the overall genetic risk has been estimated to range from 30% to 50%, it has never been studied in the French west-Indian population.

02

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • Rheumatoid Arthritis according to ACR criteria of diagnosis
03

In context

Arthritis

3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.

This study's planned enrollment of 200 is above the median of 155 across 1,057 observational studies indexed under Arthritis.

Browse Arthritis studies →

Lead sponsor

University Hospital Center of Martinique is the lead sponsor of 77 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Residents of Martinique with at least 3 African-Caribbean grandparents

Eligibility criteria

Inclusion Criteria:

  • Diagnosis of Rheumatoid Arthritis according to ACR criteria
  • Come from French West Indies (At least 3 grandparents are African-Caribbean)
  • Sign written informed consent

Exclusion Criteria:

  • Minor
  • Patient with no Rheumatoid Arthritis according to ACR criteria
  • Patient does not agree for a genetic study

For the control

Inclusion Criteria:

  • Blood donor
  • Sign written informed consent
  • Patient with no Rheumatoid Arthritis according to ACR criteria
  • Come from French West Indies (At least 3 grandparents are African-Caribbean)

Exclusion Criteria:

  • Minor
  • Patient does not agree for a genetic study
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (estimated)
Biospecimen retention
Samples with dna

Interventions

  • BiologicalCollect of 10 ml of peripheric blood for DNA extraction

    After signed written consent, all patients have a clinic exam in order to assess the presence of eligibility criteria (Patient with Rheumatoid Arthritis that fulfil the ACR criteria of diagnosis)

    Also known as: Rheumatoid Arthritis, French West-Indian Patients with Rheumatoid Arthritis

06

What researchers measure

Primary outcomes

  1. Difference of distribution of HLA alleles in patients and in healthy controls

    Time frame: 1 day

Secondary outcomes

  1. The association between the different HLA alleles among French West-Indian RA patients and the autoantibodies production.

    Time frame: 1 day

  2. The association between the different HLA alleles among French West-Indian RA patients and the radiological damage.

    Time frame: 1 day

  3. The association between the different HLA alleles among French West-Indian RA patients and the response to therapy

    Time frame: 1 day

07

Study locations

1 site
  • Service de rhumatologie CHU de Fort-de-France
    Fort-de-France, 97261, Martinique
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 21, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01111357
Lead sponsor
University Hospital Center of Martinique
First posted
Apr 27, 2010
Start date
Feb 2010
Primary completion
Aug 2010
Completion
Aug 2010
Last update
Dec 21, 2010

Study contacts

Georges JEAN-BAPTISTE, Professor of medecine
principal investigator · CHU de Fort-de-France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion